HHS Allocates Regeneron Therapeutic to Treat Patients With Mild to Moderate COVID-19
WASHINGTON, D.C. — The U.S. Department of Health and Human Services recently announced plans to allocate initial doses of Regeneron’s investigational monoclonal antibody therapeutic, casirivimab and imdevimab, which received emergency …
Read More